Posts Tagged ‘Glaucoma’
Inotek May Be for Sale, But Who Will Buy?
With another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding a buyer could be difficult. The dominoes started to fall in January, when Inotek reported that the trial of monotherapy trabodenoson did not achieve the results it was looking for.…
Read MoreWith CE Mark for Glaucoma Microsensor in Pocket, Implandata Looks to US
Now that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining up funding to launch US trials in 2018, company managing director Max Ostermeier tells OIS Weekly in an exclusive podcast. It’s no coincidence that the company’s initials – IOP –…
Read MoreDéjà vu: Aerie Announces Mercury 2 Results, Stock Jumps
With the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar into rarified air, reaching an all-time high above $55, about 38% higher than before the announcement – and even those pre-announcement prices were in record territory for the stock. If…
Read MoreAXIM Rolls Medical Marijuana Ball in Ophthalmology
Medical marijuana has quickly gained acceptance as a viable treatment for a variety of health conditions, such as the side effects of chemotherapy, the neurodegenerative effects of Alzheimer’s disease, certain seizures and chronic pain without the addictive effects of opioids. But in ophthalmology, medical marijuana has encountered the headwinds of controversy. The American Glaucoma Society…
Read MoreWhat’s Behind the Heat-up in Glaucoma Innovation
Kicking off the sixth annual Glaucoma 360-New Horizons Forum held recently in San Francisco, co-founder and co-chair Adrienne Graves boldly proclaimed, “Glaucoma is hot.” However, over the past few years, glaucoma has been anything but hot. Stone cold may be more like it. Innovation had been sorely lacking and the $5 billion annual global market…
Read MoreEye on Five – November Edition
Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and the NASDAQ Biotech Index surging 11.2%. The gains have since trailed off, but the latter index was still up 8% for November at month-end. Three anticipated policy changes have fueled…
Read MoreInnFocus
InnFocus, a Santen company, is pioneering novel surgical solutions for treating glaucoma. The company is positioned to be the first FDA approved minimally invasive stand-alone procedure for mild, moderate, and severe stage open angle Glaucoma, that lowers and sustains IOP under 15 mmHg, and completely eliminates eye drop medications in most patients. The Company is…
Read MoreHow Hot is MIGS?
The string of approvals and acquisitions in the microinvasive glaucoma surgery space has been one of ophthalmology’s more promising stories. The news shone a bright stage light on what had been one of ophthalmology’s lower-profile sectors. But just how hot is MIGS getting? Followers of the MIGS space have likely been pondering that very question…
Read MoreGraybug Could File GB-102 IND Next Year
Jeffrey Cleland, president and CEO, Graybug Vision, delivered an update on its two treatments for wet age-related macular degeneration (Wet AMD) and glaucoma. The company is working with an approved cancer treatment, Sutent, which has demonstrated the ability to restore vision in patients who also suffer from Wet AMD. An animal study of the company’s…
Read MoreOcular Therapeutix: Intravitreal Depot Technology for Retinal Drug Delivery
Ocular Therapeutix has built a portfolio of products around its proprietary hydrogel technology. ReSure Sealant is FDA approved for sealing clear corneal incisions following cataract surgery, Dextenza (dexamethasone intracanalicular depot) is in Phase III for ocular allergy and post-surgical pain, and a sustained-release travoprost depot is entering Phase III for glaucoma. The same proprietary hydrogel…
Read MoreAerie Ready for Data Release Later This Year
COO Tom Mitro visits with OISTV to give an update on Aerie’s clinical trial progress. 00:25 – Update on Rhopressa. What’s the good news? 00:39 – Data due on Mercury1 00:57 – Aerie will deliver some scoops at OIS@AAO 01:10 – What’s the goal for ASCRS? 01:25 – Is it challenging to recruit patients for…
Read MoreForSight Reports on Phase II Bimatoprost Ring Results
Phase II results of ForSight Vision5’s bimatoprost ocular ring insert have shown the ring achieves clinically significant reductions in intraocular pressure (IOP) over six months with an acceptable level of safety and tolerability, principal investigator James D. Brandt, MD, reported at OIS@ASCRS. The results were just published online in the journal Ophthalmology. The bimatoprost ring…
Read More